drugset
drugset / Trial / NCT00783341

Study of the Safety, Tolerability, and Pharmacokinetics of GAP-134 Administered Intravenously

NCT00783341 ↗

Phase 1 Completed 25 enrolled Wyeth is now a wholly owned subsidiary of Pfizer
RandomizedSingle-groupDouble-blindTreatment

Summary

This study will evaluate the safety, tolerability, and pharmacokinetics (PK) of ascending doses of GAP 134 administered as 6-day continuous IV infusions to healthy subjects.

Timeline

Start
2008-11
Primary completion
2009-02
Completion
2009-02

Drugs

EvaluationDrugModalityDoseRoute
Subject Danegaptide Peptide — Intravenous

Indications

No indication recorded.